It’s always been a story about two people loving each other fiercely in every universe, about friendship stronger than the ...

Facing the 1,090 names of the Lynnfield men and women who served for this country is an engraved bronze plaque that reads “All Gave Some, Some Gave All”. Confronted with the sheer scope of the ...

Britain’s Gen Z are broadly happy, but that happiness is declining. In the past, happiness followed a U-shape: people start happy, get sadder as they move into adulthood; then later in life, rebound ...

As the first month of the new year winds down, it's a good time to take existing goals to the next level - or to chart a new course entirely. With Aquarius season now underway, you have the full power ...

Alex Mahon, the CEO of Channel 4 has called for urgent joint industry action and also regulation to ensure that younger people can find “verified, independent news” easily on social media.

Jewelry is a vital extension of self-expression that helps people improve their personal style and taste in a small but ...

As previously reported, Compass Point analyst Joe Flynn initiated coverage of Applied Digital (APLD) with a Buy rating and $10 price target The firm, which notes that its target offers 50% upside ...

As previously reported, Compass Point upgraded Affirm (AFRM) to Neutral from Sell with a price target of $61, up from $20. The firm’s previous valuation “underappreciated” Affirm’s ability ...

Fintel reports that on January 28, 2025, Compass Point downgraded their outlook for Synchrony Financial (LSE:0LC3) from Buy to Neutral. As of January 29, 2025, the average one-year price target ...

Compass Point analyst Casey Alexander reiterated a Buy rating on RLI (RLI – Research Report) today and set a price target of $82.00. The company’s shares closed last Friday at $72.48.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Metals & Mining industry for Thursday, January 30, 2025. Let’s ...

Compass also caused jitters amongst its investors as it revealed that it will shift the data readout for phase 3 trials of the psilocybin-based COMP360 therapy until after the 26-week time point ...